CoChat

Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis

Open access
Corpechot, Christophe, Chazouillères, Olivier, Belnou, Pierre, Montano-Loza, Aldo J., Mason, Andrew, Ebadi, Maryam, Eurich, Dennis, Chopra, Sascha, Jacob, Dietmar, Schramm, Christoph, Sterneck, Martina, Bruns, Tony, Reuken, Philipp, Rauchfuss, Falk, Roccarina, Davide, Thorburn, Douglas, Gerussi, Alessio, Trivedi, Palak, Hirschfield, Gideon, McDowell, Patrick, Nevens, Frederik, Boillot, Olivier, Bosch, Alexie, Giostra, Emiliano, Conti, Filomena, Poupon, Raoul, Parés, Albert, Reig, Anna, Donato, Maria Francesca, Malinverno, Federica, Floreani, Annarosa, Russo, Francesco Paolo, Cazzagon, Nora, Verhelst, Xavier, Goet, Jorn, Harms, Maren, van Buuren, Henk, Hansen, Bettina, Carrat, Fabrice, Dumortier, Jérôme · 2020 · Journal of Hepatology
Cited by 87

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

BACKGROUND & AIMS: Recurrence of primary biliary cholangitis (PBC) after liver transplantation (LT) is frequent and can impair graft and patient survival. Ursodeoxycholic acid (UDCA) is the current standard therapy for PBC. We investigated the effect of preventive exposure to UDCA on the incidence and long-term consequences of PBC recurrence after LT. METHODS: We performed a retrospective cohort study in 780 patients transplanted for PBC, between 1983-2017 in 16 centers (9 countries), and followed-up for a median of 11 years. Among them, 190 received preventive UDCA (10-15 mg/kg/day). The primary outcome was histological evidence of PBC recurrence. The secondary outcomes were graft loss, liver-related death, and all-cause death. The association between preventive UDCA and outcomes was quantified using multivariable-adjusted Cox and restricted mean survival time (RMST) models. RESULTS: While recurrence of PBC significantly shortened graft and patient survival, preventive exposure to UDCA was associated with reduced risk of PBC recurrence (adjusted hazard ratio [aHR] 0.41; 95% CI 0.28-0.61; p <0.0001), graft loss (aHR 0.33; 95% CI 0.13-0.82; p <0.05), liver-related death (aHR 0.46; 95% CI 0.22-0.98; p <0.05), and all-cause death (aHR 0.69; 95% CI 0.49-0.96; p <0.05). On RMST analysis, preventive UDCA led to a survival gain of 2.26 years (95% CI 1.28-3.25) over a period of 20 years. Exposure to cyclosporine rather than tacrolimus had a complementary protective effect alongside preventive UDCA, reducing the cumulative incidence of PBC recurrence and all-cause death. CONCLUSIONS: Preventive UDCA after LT for PBC is associated with a reduced risk of disease recurrence, graft loss, and death. A regimen combining cyclosporine and preventive UDCA is associated with the lowest risk of PBC recurrence and mortality. LAY SUMMARY: Recurrence of primary biliary cholangitis after liver transplantation is frequent and can impair graft and patient survival. We performed the largest international study of transplanted patients with primary biliary cholangitis to date. Preventive administration of ursodeoxycholic acid after liver transplantation was associated with reduced risk of disease recurrence, graft loss, liver-related and all-cause mortality. A regimen combining cyclosporine and preventive ursodeoxycholic acid was associated with the best outcomes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2020.03.043

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 87

Metadata

Authors
Corpechot, C., Chazouillères, O., Belnou, P., Montano-Loza, A. J., Mason, A., Ebadi, M., Eurich, D., Chopra, S., Jacob, D., Schramm, C., Sterneck, M., Bruns, T., Reuken, P., Rauchfuss, F., Roccarina, D., Thorburn, D., Gerussi, A., Trivedi, P., Hirschfield, G., McDowell, P., Nevens, F., Boillot, O., Bosch, A., Giostra, E., Conti, F., Poupon, R., Parés, A., Reig, A., Donato, M. F., Malinverno, F., Floreani, A., Russo, F. P., Cazzagon, N., Verhelst, X., Goet, J., Harms, M., van Buuren, H., Hansen, B., Carrat, F., & Dumortier, J.
Venue
Journal of Hepatology
Publisher
Elsevier BV
Published
2020-09
Volume
73
Issue
3
Pages
559-565
ISSN
0168-8278 (ISSN-L)
OpenAlex
W3015823489
Cited by
87
References
12
FWCI
5.66
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis. https://app.cochat.ai/papers/10.1016/j.jhep.2020.03.043
The paper
Corpechot, C., Chazouillères, O., Belnou, P., Montano-Loza, A. J., Mason, A., Ebadi, M., Eurich, D., Chopra, S., Jacob, D., Schramm, C., Sterneck, M., Bruns, T., Reuken, P., Rauchfuss, F., Roccarina, D., Thorburn, D., Gerussi, A., Trivedi, P., Hirschfield, G., . . . Dumortier, J. (2020). Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis. Journal of Hepatology. https://doi.org/10.1016/j.jhep.2020.03.043

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.